|[February 27, 2013]
Finkelstein Thompson LLP Announces Investigation Of Affymax, Inc.
WASHINGTON --(Business Wire)--
The law firm Finkelstein Thompson LLP is investigating potential claims
on behalf of shareholders of Affymax, Inc. ("Affymax" or "the Company")
(Nasdaq: AFFY). Finkelstein Thompson's investigation relates to the
recent announcement by Affymax and partner Takeda Pharmaceutical that
they were voluntarily recalling all lots of Omontys, Affymax's flagship
Affymax's recall allegedly resulted from reports of severe allergic
reactions in some kidney-disease patients, culminating in at least five
deaths. On Sunday, February 24, 2013, the U.S. Food and Drug
Administration alerted healthcare providers about the Omontys recall.
The next day -- Monday, February 25, 2013 -- Affymax's share price
plumeted as much as 85% from the Friday's close. The investigation
focuses on whether Affymax violated state or federal laws in connection
with its public statements regarding Omontys's side effects and the
subsequent recall of the drug.
If you are interested in discussing your rights as an Affymax
shareholder, or have information relating to this investigation, please
contact Finkelstein Thompson's Washington, DC offices at (202)-337-8000
or by email at email@example.com.
Finkelstein Thompson LLP has spent over three decades delivering
outstanding representation to institutional and individual clients in
financial litigation, and has been appointed as lead or co-counsel in
dozens of shareholder class actions. Indeed, the firm has served in
leadership roles in cases that have recovered over $1 billion for
investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our website
Attorney advising. Prior results do not guarantee similar outcomes.
[ Back To TMCnet.com's Homepage ]